TiGenix reports 2017 full year results

NEXT STORY
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE “TRANSPARENCY LAW”)
PREV STORY
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE “TRANSPARENCY LAW”)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

TiGenix reports 2017 full year results

NEXT STORY
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE “TRANSPARENCY LAW”)
PREV STORY
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE “TRANSPARENCY LAW”)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Insmed Submits New Drug Application to FDA for ALIS in NTM Lung Disease Caused by MAC

ALIS previously designated as an orphan drug, breakthrough therapy and Qualified Infectious Disease Product ...

author_avatar
NASDAQ Market News

eFFECTOR Announces Appointment of John W. Smither to its Board of Directors

SAN DIEGO, March 23, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in ...

author_avatar
NASDAQ Market News

BeiGene Announces Commercial Availability of VIDAZA® (Azacitidine for Injection) in China

BEIJING, China, and CAMBRIDGE, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), ...

author_avatar
NASDAQ Market News